Sarepta Therapeutics Inc
SRPT
Market Cap$10.94B
Close$
$153.22
23.3% upside
Current Fair Value
23.3% upsideUndervalued by 23.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.94 Billion |
|---|---|
| Enterprise Value | $10.51 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.8 |
| Beta | 0.0 |
| Outstanding Shares | 93,900,000 |
| Avg 30 Day Volume | 602,166 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -20.42 |
|---|---|
| PEG | 14.4 |
| Price to Sales | 9.56 |
| Price to Book Ratio | 13.81 |
| Enterprise Value to Revenue | 8.45 |
| Enterprise Value to EBIT | -39.23 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 1.44 |
Revenue Sources
No data
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...